A Open-label, Multicenter Phase II Study of TQ-B3525 Tablets in Subjects With PIK3CA and/or PIK3R1/2 Gene-altered Recurrent/Metastatic Advanced Gynecologic Tumors
Latest Information Update: 05 Apr 2023
At a glance
- Drugs TQ-B3525 (Primary)
- Indications Cervical cancer; Endometrial cancer; Ovarian cancer
- Focus Therapeutic Use
- Sponsors Chia Tai Tianqing Pharmaceutical Group
Most Recent Events
- 09 Apr 2021 New trial record